Reich K, et al. - Researchers conducted a pooled analysis of the randomized studies VOYAGE 1 and VOYAGE 2 to test the safety of guselkumab during 100 weeks in patients with moderate-to-severe psoriasis. For this investigation, patients were randomized to 100 mg guselkumab at weeks 0 and 4 and every 8-weeks thereafter; placebo at weeks 0, 4, 12 followed by guselkumab 100 mg at weeks 16 and 20 and every 8 weeks thereafter; or adalimumab 80 mg at weeks 0, 40 mg at weeks 1 and 40 mg every 2 weeks thereafter. During 100 weeks of treatment, the safety profile for guselkumab remains favorable in patients with moderate-to-severe psoriasis.